Print this page
-
A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination with Chemotherapy versus Placebo with Chemotherapy in Patients with Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease.
Protocol: 042601Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A PHASE Ib/II MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-4198 ALONE AND IN COMBINATION WITH GIREDESTRANT IN COMPARISON WITH ABEMACICLIB AND GIREDESTRANT IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER WHO HAVE PREVIOUSLY PROGRESSED DURING OR AFTER A CDK4/6 INHIBITOR
Protocol: 042505Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer Using ctDNA and HARPS Biomarker Assay.
Protocol: 042507Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination with Chemotherapy versus Placebo with Chemotherapy in Patients with Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease.
Protocol: 042601Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment.
Protocol: 072504Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Breast
Colon
Esophagus
Larynx
Lip, Oral Cavity and Pharynx
Other Digestive Organ
Pancreas
Rectum
Small Intestine
Stomach -
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment.
Protocol: 072504Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Breast
Colon
Esophagus
Larynx
Lip, Oral Cavity and Pharynx
Other Digestive Organ
Pancreas
Rectum
Small Intestine
Stomach -
The Women's Circle of Health Study.
Protocol: 130404Principal Investigator:
- Elisa V Bandera
Applicable Disease Sites: Breast - Female -
Adapting and Implementing Evidence-Based Breast Cancer Follow-up in Primary Care.
Protocol: 132103Principal Investigator:
- Shawna Hudson
Applicable Disease Sites: Breast -
Cancer Analytics and South Asian Health Breast Cancer Survivor Study (CANSAH-BC).
Protocol: 132204Applicable Disease Sites: Breast
-
Personalized Oncology Promoting Equity for Black Lives (PROPEL).
Protocol: 132309Principal Investigator:
- Anita Y Kinney
Applicable Disease Sites: Breast
Colon
Corpus Uteri
Ovary
Pancreas
Prostate -
ACCESS-PC: Advancing Care Coordination to Enhance Shared Care for Complex Survivors in Primary Care
Protocol: 132402Applicable Disease Sites: Breast
Corpus Uteri
Prostate
Urinary Bladder -
A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Cancers of the Stomach, Breast, Lung and Cervix.
Protocol: 192004Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Any Site
Breast
Cervix
Lung
Stomach -
A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers.
Protocol: 192104Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Breast
Cervix
Lip, Oral Cavity and Pharynx
Other Female Genital
Other Male Genital
Stomach -
The Women's Circle of Health Study.
Protocol: 130404Principal Investigator:
- Elisa V Bandera
Applicable Disease Sites: Breast - Female -
Adapting and Implementing Evidence-Based Breast Cancer Follow-up in Primary Care.
Protocol: 132103Principal Investigator:
- Shawna Hudson
Applicable Disease Sites: Breast -
Cancer Analytics and South Asian Health Breast Cancer Survivor Study (CANSAH-BC).
Protocol: 132204Applicable Disease Sites: Breast